Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Validation of a methylation-based, tissue-free MRD assay in colorectal cancer patients from the GALAXY study.

The methylation-based tissue-free Latitude assay was tested on 1,230 time points from 195 people in GALAXY, and ctDNA positivity was associated with worse disease-free survival in both the residual-disease and surveillance windows.

NPJ Precision OncologyPubMed 41555007DOI 10.1038/s41698-026-01277-5